These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37276913)

  • 21. Prospective direct comparison of antihypertensive effect and safety between high-dose amlodipine or indapamide in hypertensive patients uncontrolled by standard doses of angiotensin receptor blockers and amlodipine.
    Okamura K; Shirai K; Totake N; Okuda T; Urata H
    Clin Exp Hypertens; 2018; 40(2):99-106. PubMed ID: 28692311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
    Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
    Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension: A Phase II Multicenter, Randomized, Double-blind Clinical Trial.
    Sohn IS; Kim CJ; Ahn T; Youn HJ; Jeon HK; Ihm SH; Cho EJ; Chung WB; Chae SC; Kim WS; Nam CW; Park SM; Choi JY; Kim YK; Hong TJ; Lee HY; Cho JH; Shin ES; Yoon JH; Yang TH; Jeong MH; Lee JH; Park JI
    Clin Ther; 2017 Aug; 39(8):1628-1638. PubMed ID: 28734660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis.
    Xie M; Tang T; Liang H
    Clin Cardiol; 2023 Aug; 46(8):886-898. PubMed ID: 37432701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initial combination therapy with irbesartan/hydrochlorothiazide for hypertension: an analysis of the relationship between baseline blood pressure and the need for combination therapy.
    Franklin S; Lapuerta P; Cox D; Donovan M
    J Clin Hypertens (Greenwich); 2007 Dec; 9(12 Suppl 5):15-22. PubMed ID: 18046108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of a quadruple ultra-low-dose treatment for hypertension (QUARTET USA): Rationale and design for a randomized controlled trial.
    Baldridge AS; Huffman MD; Lazar D; Abbas H; Flowers FM; Quintana A; Jackson A; Khan SS; Chopra A; Vu M; Tripathi P; Jacobson T; Sanuade OA; Kandula NR; Persell SD; Paparello JJ; Rosul LL; Mejia J; Lloyd-Jones DM; Chow CK; Ciolino JD
    Am Heart J; 2022 Dec; 254():183-193. PubMed ID: 36116516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension.
    Calhoun DA; Lacourcière Y; Crikelair N; Jia Y; Glazer RD
    Curr Med Res Opin; 2013 Aug; 29(8):901-10. PubMed ID: 23721363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Fimasartan/Amlodipine Combined Therapy Versus Fimasartan Monotherapy in Patients With Essential Hypertension Unresponsive to Fimasartan Monotherapy.
    Kim KI; Shin MS; Ihm SH; Youn HJ; Sung KC; Chae SC; Nam CW; Seo HS; Park SM; Rhee MY; Kim MH; Cha KS; Kim YJ; Kim JJ; Chun KJ; Yoo BS; Park S; Shin ES; Kim DS; Il Kim D; Kim KH; Joo SJ; Jeong JO; Shin J; Kim CH
    Clin Ther; 2016 Oct; 38(10):2159-2170. PubMed ID: 27502326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, randomized, double-blind, noninferiority study.
    Lee IT; Hung YJ; Chen JF; Wang CY; Lee WJ; Sheu WH
    Clin Ther; 2012 Aug; 34(8):1735-50. PubMed ID: 22784975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
    Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
    Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of increasing calcium channel blocker dose vs. adding a diuretic to treatment regimens for patients with uncontrolled hypertension.
    Tani S; Asayama K; Oiwa K; Harasawa S; Okubo K; Takahashi A; Tanabe A; Ohkubo T; Hirayama A; Kushiro T
    Hypertens Res; 2017 Oct; 40(10):892-898. PubMed ID: 28446804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of efficacy and tolerability of amlodipine orotate versus amlodipine besylate in adult patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group, 8-week follow-up, noninferiority trial.
    Hong SJ; Ahn TH; Baek SH; Cho WH; Jeon HK; Kwan J; Yoon MH; Lee KJ; Lim DS
    Clin Ther; 2006 Apr; 28(4):537-51. PubMed ID: 16750465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Fixed-dose Combinations of Amlodipine/Losartan Potassium/Chlorthalidone and Amlodipine/Losartan Potassium in Patients With Stage 2 Hypertension Inadequately Controlled With Amlodipine/Losartan Potassium: A Randomized, Double-blind, Multicenter, Phase III Study.
    Hong SJ; Jeong HS; Han SH; Chang KY; Hong BK; Lee BK; Chae SC; Kim WS; Park CG; Heo JH; Lee SU; Kim YD; Kim KS; Choi JH; Kang HJ; Kim JJ; Kang SM; Choi YJ; Shin JH; Chun KJ; Shin DG; Park SH; Kwan J; Choi YJ; Jeong MH; Chae JK; Kim DW; Cho JR; Han KR; Won KH; Park SH; Lee SK; Kim SH; Jung J; Kim CH
    Clin Ther; 2017 Oct; 39(10):2049-2060. PubMed ID: 28939406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the efficacy and safety of fixed-dose amlodipine/losartan and losartan in hypertensive patients inadequately controlled with losartan: a randomized, double-blind, multicenter study.
    Hong BK; Park CG; Kim KS; Yoon MH; Yoon HJ; Yoon JH; Yang JY; Choi YJ; Cho SY
    Am J Cardiovasc Drugs; 2012 Jun; 12(3):189-95. PubMed ID: 22462558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension.
    Oparil S; Barr E; Elkins M; Liss C; Vrecenak A; Edelman J
    Clin Ther; 1996; 18(4):608-25. PubMed ID: 8879890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.
    Gradman AH; Schmieder RE; Lins RL; Nussberger J; Chiang Y; Bedigian MP
    Circulation; 2005 Mar; 111(8):1012-8. PubMed ID: 15723979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension.
    Pool JL; Guthrie RM; Littlejohn TW; Raskin P; Shephard AM; Weber MA; Weir MR; Wilson TW; Wright J; Kassler-Taub KB; Reeves RA
    Am J Hypertens; 1998 Apr; 11(4 Pt 1):462-70. PubMed ID: 9607385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative efficacy and safety profile of amlodipine 5 mg/losartan 50 mg fixed-dose combination and amlodipine 10 mg monotherapy in hypertensive patients who respond poorly to amlodipine 5 mg monotherapy: an 8-week, multicenter, randomized, double-blind phase III noninferiority study.
    Kang SM; Youn JC; Chae SC; Park CG; Yang JY; Kim MH; Hong TJ; Kim CH; Kim JJ; Shin DG; Jeong JW; Yoon JH; Park SH; Kwon J; Cho SY
    Clin Ther; 2011 Dec; 33(12):1953-63. PubMed ID: 22136978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blood pressure-lowering efficacy and safety of perindopril/indapamide/amlodipine single-pill combination in patients with uncontrolled essential hypertension: a multicenter, randomized, double-blind, controlled trial.
    Mourad JJ; Amodeo C; de Champvallins M; Brzozowska-Villatte R; Asmar R;
    J Hypertens; 2017 Jul; 35(7):1481-1495. PubMed ID: 28306636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.